LaserSight's LaserScan LSX Will Be Sold By Six U.S. Direct Sales Reps
This article was originally published in The Gray Sheet
LaserSight will seek approval of its LaserScan LSX laser assisted in situ keratomileusis (LASIK) system for correction of farsightedness (hyperopia).
You may also be interested in...
LaserSight says it will delay marketing of the LaserScan LSX ophthalmic excimer laser system in the U.S. while it negotiates a license agreement with competitor Visx.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.